Amicus Therapeutics, Inc. (FOLD)
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Investigation
11/08/2021
Initial Lawsuit
01/10/2022
Lawsuit Progression
03/25/2022
Investigation following Oak Street Health’s disclosure of a U.S. Department of Justice (DOJ) civil investigative demand concerning potential violation of the False Claims Act.
11/08/2021
Oak Street files its Q3 2021 quarterly peport with the SEC on Form 10-Q disclosing that on November 1, 2021, it received a civil investigative demand (CID) from the United States Department of Justice (DOJ).
“According to the CID, the Department of Justice is investigating whether the Company may have violated the False Claims Act, 31 U.S.C. §§ 3729-3722. The CID requests certain documents and information related to the Company’s relationships with third party marketing agents and related to the Company’s provision of free transportation to federal health care beneficiaries and requests information and documents related to such matters. We intend to cooperate with the Department of Justice and produce information and documentation in response to the CID. . .“
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$37.14 | $46.89 | $-9.75 | -20.79% |
This is a class action on behalf of persons and entities that purchased or otherwise acquired Oak Street securities between August 6 2020, and November 8, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(1) that Oak Street maintained relationships with third-party marketing agents likely to provoke law enforcement scrutiny;
(2) that Oak Street was providing free transportation to federal health care beneficiaries in a manner that would provoke law enforcement scrutiny;
(3) that these activities may be violations of the False Claims Act;
(4) that, as such, Oak Street was at heightened risk of investigation by the Department of Justice and/or other federal law enforcement agencies;
(5) that, as a result, Oak Street was subject to adverse impacts related to defense and settlement costs and diversion of management resources; and
(6) that, as a result of the foregoing, defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
03/25/2022
The court issued an order appointing the lead plaintiff and lead counsel.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.